SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010; 69 Suppl I: i229.
  • 2
    Diel R, Loddenkemper R, Meywald-Walter K, Gottschalk R, Nienhaus A. Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold In Tube Assay, and T Spot TB test in contact investigations for tuberculosis. Chest 2009; 135: 10108.
  • 3
    Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. Comparison of an interferon-γ assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008; 35: 77681.
  • 4
    Sellam J, Hamdi H, Roy C, Baron G, Lemann M, Puechal X, et al, for the RATIO (Research Axed on Tolerance of Biotherapies) Study Group. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007; 66: 16105.
  • 5
    Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis. Br J Dermatol 2007; 156: 10104.
  • 6
    Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151 Suppl 69: 317.
  • 7
    Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 3729.
  • 8
    Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 14855.
  • 9
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098104.
  • 10
    Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005; 44: 71420.
  • 11
    Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, on behalf of the BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 21227.
  • 12
    Inanc N, Aydin SZ, Karakurt S, Atagunduz P, Yavuz S, Direskeneli H. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2009; 36: 267581.
  • 13
    Dinser R, Fousse M, Sester U, Albrecht K, Singh M, Kohler H, et al. Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-α blocking drugs using a novel flow-cytometric interferon-γ release assay. Rheumatology (Oxford) 2008; 47: 2128.
  • 14
    Greenberg JD, Reddy SM, Schloss SG, Kurucz OS, Bartlett SJ, Abramson SB, et al. Comparison of an in vitro tuberculosis interferon-γ assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. J Rheumatol 2008; 35: 7705.
  • 15
    Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay. Ann Rheum Dis 2008; 67: 8490.
  • 16
    Kobashi Y, Mouri K, Obase Y, Fukuda M, Miyashita N, Oka M. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J 2007; 30: 94550.
  • 17
    Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, et al. Routine hospital use of a new commercial whole blood interferon-γ assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2005; 172: 6315.
  • 18
    Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis 2005; 24: 52936.
  • 19
    Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis [published erratum appears in Arthritis Rheum 2010;62:2812]. Arthritis Rheum 2009: 60: 227283.
  • 20
    Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68: 78996.
  • 21
    Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four–week efficacy and safety results of a randomized, placebo-controlled study [published erratum appears in Arthritis Rheum 2010;62:2555]. Arthritis Rheum 2009; 60: 97686.
  • 22
    Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 340212.
  • 23
    Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al, for the GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374: 21021.
  • 24
    QuantiFERON-TB Gold clinicians guide and QuantiFERON-TB Gold In-Tube Method [package insert]. Valencia (CA): Cellestis; 2010.
  • 25
    Centers for Disease Control and Prevention / American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000; 49: 151.
  • 26
    Centers for Disease Control and Prevention. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR 2010; 59: 125.
  • 27
    Richeldi L, Losi M, D'Amico R, Luppi M, Ferrari A, Mussini C, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009; 136: 198204.
  • 28
    Cobanoglu N, Ozcelik U, Kalyoncu U, Ozen S, Kiraz S, Gurcan N, et al. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Int J Tuberc Lung Dis 2007; 11: 117782.
  • 29
    Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, et al. Performance of two commercial blood IFN-γ release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-α treatment. Eur J Clin Microbiol Infect Dis 2008; 27: 90713.
  • 30
    Kim EY, Lim JE, Jung JY, Son JY, Lee KJ, Yoon YW, et al. Performance of the tuberculin skin test and interferon-γ release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis 2009; 9: 207.
  • 31
    Jones S, de Gijsel D, Wallach FR, Gurtman AC, Shi Q, Sacks H. Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals. Int J Tuberc Lung Dis 2007; 11: 11905.
  • 32
    Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, et al. Comparison of an interferon-γ release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175: 73742.
  • 33
    Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 17784.
  • 34
    Schoepfer AM, Flogerzi B, Fallegger S, Schaffer T, Mueller S, Nicod L, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 2799806.
    Direct Link:
  • 35
    Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-γ test. Respir Res 2006; 7: 56.
  • 36
    Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367: 132834.
  • 37
    Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-γ release assay in HIV-1-infected individuals. Clin Infect Dis 2009; 48: 95462.
  • 38
    Higuchi K, Harada N, Fukazawa K, Mori T. Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis. Tuberculosis (Edinb) 2008; 88: 2448.
  • 39
    Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-γ assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177: 116470.
  • 40
    Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al, for the START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006; 54: 107586.